Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a leader in liquid biopsy technology, will release its preliminary results for the year ending December 31, 2021, on April 28, 2022. An analyst meeting is scheduled for 10:00 am BST at Berenberg's London office. A live webcast will be available on ANGLE's Investor Centre page, with a recording accessible later. ANGLE's technology includes the Parsortix system, a liquid biopsy tool designed for comprehensive cancer analysis, and has received a CE Mark in Europe, with an FDA submission underway for use in metastatic breast cancer patients.
ANGLE plc presented results from its Parsortix system at the AACR 2022 conference, showcasing its effectiveness in analyzing circulating tumor cells (CTCs) from triple negative breast cancer (TNBC) patients. The poster highlighted a higher positivity rate for CTCs compared to alternative methods, particularly noting the presence of mesenchymal phenotype CTCs and clusters. This technology supports longitudinal monitoring in cancer drug trials and is part of ANGLE's pharma services. The Parsortix system is designed for non-invasive cancer analysis and has a strong patent portfolio in multiple countries.
ANGLE plc announced results from the Molecular Oncology Laboratory at ETH Zurich, demonstrating the effectiveness of its Parsortix system in isolating circulating tumor cells (CTCs) for identifying actionable drug targets in metastatic breast cancer. The study revealed specific genes involved in metastasis, where their inhibition reduced CTC cluster formation and metastatic potential. Given that ~90% of cancer deaths are due to metastasis, this research highlights the Parsortix system's capability in advancing targeted therapies, potentially improving patient outcomes. The findings are peer-reviewed and published in Cancer Research.
ANGLE plc has announced promising research results from the University of Maryland regarding its Parsortix system for liquid biopsy. The study, focusing on triple-negative breast cancer (TNBC), demonstrated that the isolation of live circulating tumor cells (CTCs) can provide quick insights into patient responses to therapies targeting metastasis. Notably, vinorelbine treatment improved the time to cancer spread significantly. As TNBC cases continue to rise, this research could enhance treatment options and offer rapid, actionable insights for patients facing limited therapies.
ANGLE plc has announced significant findings from a study on triple negative breast cancer (TNBC) using their Parsortix system. Conducted by the Fondazione IRCCS Istituto Nazionale dei Tumori, the research shows that Parsortix can harvest intact circulating tumor cells (CTCs) for whole genome sequencing, identifying actionable genetic targets. The study revealed treatment-induced resistance and highlights the utility of CTC analysis for personalized medicine in patients with limited treatment options. The findings have been published in Scientific Reports.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has received a Certificate of Registration from the Centers for Medicare and Medicaid Services (CMS) for its US clinical laboratory, marking a significant step towards achieving CLIA accreditation.
This accreditation will enable the laboratory to process samples for patient management across most US states. Following a CMS audit, a Certificate of Compliance will be issued. With laboratory accreditation progressing in both the US and UK, ANGLE aims to enhance its commercial offerings and support its pharma services business, as noted by Chief Medical Officer, Dr. Todd Druley.
ANGLE plc announced that as of February 25, 2022, Morgan Stanley Investment Management Inc. has reduced its voting rights in the company to 4.82%, down from a previous holding above 5%. The notification reflects a significant change in the investment management strategy of Morgan Stanley, which now manages 11,328,548 voting rights in ANGLE plc. This marks a notable shift since they previously surpassed the threshold in January 2021 with a holding of 5.32%.
ANGLE plc has issued 6,667 new ordinary shares following the exercise of employee options, increasing the total shares to 235,149,717. These shares will be admitted to trading on AIM, effective 8:00 a.m. on February 24, 2022. The company is recognized for its innovative liquid biopsy technology, including the Parsortix system, which enables effective analysis of circulating tumor cells (CTCs). ANGLE aims to be the first to receive FDA clearance for CTC harvesting, enhancing its competitive position in the oncology market.
ANGLE plc announces a peer-reviewed study from Edith Cowan University demonstrating the effectiveness of the Parsortix system in isolating circulating tumor cells (CTCs) in ovarian cancer patients. The study shows a significant correlation between PD-L1 expression and CTCs undergoing epithelial to mesenchymal transition (EMT). Among 16 patients, 63% had detectable CTCs, with 50% being PD-L1 positive. The results suggest that using the Parsortix system could enhance patient selection for immunotherapy, addressing the need for improved treatment outcomes where current response rates are low.
ANGLE plc announced a groundbreaking study establishing the concordance of its Parsortix liquid biopsy blood test with invasive tissue biopsy in metastatic breast cancer (MBC) patients. Conducted by experts at the University of Southern California, the study indicates that over 50% of MBC patients are unable to undergo successful tissue biopsies due to various factors. With a pilot study involving 19 patients, the Parsortix test demonstrated high concordance in RNA sequencing results, potentially offering a non-invasive alternative to guide treatment decisions effectively. This research contributes significant insights into cancer monitoring and personalized therapy.